|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 5,866,581: Scope, Claims, and Patent Landscape
Summary
US Patent 5,866,581, titled "Methods and Compositions for the Treatment of Diseases with Biphosphonates", was granted in 1999 and is held by Eli Lilly and Company. The patent covers specific formulations of bisphosphonates—medications primarily used in the treatment of metabolic bone diseases, such as osteoporosis and Paget’s disease—as well as methods for their use in treating various conditions related to abnormal bone resorption.
This patent's scope encompasses novel compositions, dosing regimens, formulations, and therapeutic methods involving bisphosphonates, particularly targeting nitrogen-containing bisphosphonates like alendronate. It forms a critical piece in the patent landscape surrounding anti-resorptive agents, influencing subsequent patent filings, generic challenges, and licensing negotiations.
This analysis delineates the detailed scope of the patent claims, contextualizes its standing amid the patent landscape, and evaluates its influence on pharmaceutical development and patent strategies.
What Are the Core Claims of US Patent 5,866,581?
Claim structure and key features:
| Claim Type |
Description |
Key Elements |
| Independent Claims |
Broad claims defining the core invention |
| Dependent Claims |
Narrower claims refining independent claims |
1. Independent Claims
Claim 1 Example (paraphrased):
A method of treating a disease associated with abnormal bone resorption in a mammal, comprising administering an effective amount of a biphosphonate compound selected from nitrogen-containing bisphosphonates, wherein the biphosphonate is administered in a specific dosing regimen to improve bone density or inhibit bone resorption.
- Scope: Encompasses any nitrogen-containing bisphosphonate, with an emphasis on novel formulations and dosing schedules.
- Implication: Focuses on both composition and method of use, including prophylactic and therapeutic applications.
2. Dependent Claims
- Cover specific compounds such as alendronate, risedronate, and other nitrogenous bisphosphonates.
- Detail dosing regimens (e.g., weekly or monthly administration).
- Specify formulations like tablets, solutions, or injectable forms.
- Include claims about treatment of specific diseases such as osteoporosis, Paget’s disease, hypercalcemia, and bone metastases.
Scope of the Patent: Definitions and Boundaries
Key Elements of the Patent Claims
| Element |
Detailed Description |
Technical Significance |
| Compounds |
Nitrogen-containing bisphosphonates, especially alendronate |
Focus on compounds with nitrogen substituents enhancing potency |
| Methods of Administration |
Oral, injectable, or other delivery forms |
Emphasizes versatility in administration routes |
| Dosing Regimens |
Specific schedules, such as weekly or monthly doses |
Addresses compliance and efficacy optimization |
| Indications |
Bone resorption diseases—osteoporosis, Paget’s, hypercalcemia |
Broad therapeutic scope |
| Formulations |
Tablets, solutions, powders |
Extends coverage to various pharmaceutical formulations |
Excluded Subject Matter
- Non-nitrogen bisphosphonates.
- Methods not involving specific dosing regimens or formulations.
- Uses unrelated to bone diseases, such as cancer treatment unrelated to bone metastasis.
Legal Boundaries
The claims are notable for their focus on administration regimens and compositions, delineating the patent's protection largely to specific dosing schedules and compound choices, rather than the general class of bisphosphonates.
Patent Landscape Context
Pre-Grant Landscape
Prior to 1999 when the patent was granted, the bisphosphonate field was active, with existing patents covering etidronate, clodronate, and pamidronate; however, nitrogen-containing bisphosphonates represented a significant innovation, with alendronate and risedronate emerging as key therapeutic agents.
Post-Grant Development and Related Patents
| Patent/Document |
Year |
Focus |
Relation to US 5,866,581 |
| WO 97/29151 |
1997 |
Nitrogen-containing bisphosphonates compounds |
Similar compounds but prior to the US patent grant |
| US 6,014,743 |
2000 |
New dosing regimens of bisphosphonates |
Cites US 5,866,581 |
| US 6,258,864 |
2001 |
Extended formulations and specific dosing schedules |
Builds upon the US patent |
Key observations:
- The US patent provided foundational claims on composition and methods that have been cited by subsequent patents, indicating its significance.
- The landscape is characterized by overlapping claims focusing on specific bisphosphonate compounds, administration methods, and treatment indications.
Legal and Patent Term Considerations
- The patent filed date: 1997; granted in 1999.
- Expected patent expiration: 20 years from the filing date, i.e., approx. 2017, subject to patent term adjustments.
- Implications: Patent expiry opens the landscape to generic formulations, subject to other filings or pediatric extension considerations.
Comparison with Key Similar Patents
| Patent Number |
Focus |
Differentiators |
Status |
| US 5,656,595 |
Clodronate formulations |
Focused on non-nitrogen bisphosphonates |
Expired |
| US 6,346,342 |
Risedronate formulations |
Post-dates US 5,866,581, builds on methods |
Active/Forceful |
| WO 97/29151 |
Nitrogen bisphosphonates |
Similar compounds, broader scope |
Pre- or post-filing |
Overall, US 5,866,581's claims remain influential as foundational for nitrogen-containing bisphosphonate treatments, with subsequent inventions refining dose, formulation, and application specifics.
Implications for Industry & Patent Strategy
| Aspect |
Impact & Consideration |
| Patent Life & Expiry |
Anticipated expiration in 2017; potential for generic competition. |
| Freedom to Operate (FTO) |
Companies developing nitrogen bisphosphonates should review whether claims overlap with their formulations, especially with specific dosing regimens. |
| Licensing Opportunities |
The patent’s broad claims make it a strategic licensing target for generic makers and biosimilar companies. |
| Formulation Development |
Innovating beyond the scope—e.g., novel delivery methods or combination therapies—may circumvent patent claims. |
Key Takeaways
- Scope: US 5,866,581 primarily protects methods and compositions involving nitrogen-containing bisphosphonates, with an emphasis on specific dosing regimens and formulations applicable to bone resorption diseases.
- Claims: Cover a broad spectrum of compounds, administration schedules, and indications but are limited to the use of nitrogen-containing bisphosphonates in treatment regimens.
- Patent Landscape: Serves as a foundational patent influencing subsequent bisphosphonate developments and formulations, with expiration around 2017.
- Strategic Positioning: The patent’s expiration allows for increased generic penetration; however, defending or designing around its claims requires detailed analysis of specific formulations and treatment methods.
- Regulatory & Market Impact: The patent underpins the commercialization of key drugs like alendronate (Fosamax), which dominated market share for osteoporosis treatment post-1999.
FAQs
1. Does US Patent 5,866,581 cover all bisphosphonate compounds?
No. It specifically targets nitrogen-containing bisphosphonates, like alendronate and risedronate, and their methods of administration, not all bisphosphonates in general.
2. Can generic companies develop bisphosphonate drugs now that the patent expired?
Yes. The patent’s expiration in 2017 means generic manufacturers can seek approval for formulations—including alendronate generics—assuming no other patent barriers or market exclusivities.
3. What are the key distinguishing features of the claims?
Primarily, the claims focus on specific dosing regimens, formulations, and the use of nitrogen-containing bisphosphonates for treating bone resorption diseases.
4. How does this patent influence current innovation?
It provided the initial framework for safe, effective bisphosphonate therapies and remains a reference point for patent filings involving similar compounds and dosing strategies.
5. Are there ongoing patent applications citing US 5,866,581?
Yes, numerous subsequent patents, especially around formulations and combination therapies, cite or build upon the original claims to extend patent protection or develop new treatment modalities.
References
- US Patent 5,866,581. "Methods and Compositions for the Treatment of Diseases with Biphosphonates," Eli Lilly and Company, 1999.
- WHO International Patent Classification (IPC) C07F7/00 for bisphosphonate core structures.
- Market reports on osteoporosis drugs (e.g., IMS Health) indicating post-expiration generic entries.
- World Patent Index (WPI) citations and subsequent filings referencing US 5,866,581.
- FDA drug approvals for alendronate (Fosamax) and their regulatory histories.
This detailed review underscores the legal scope, strategic relevance, and evolution of US Patent 5,866,581 within the anti-resorptive pharmaceutical landscape, serving as a critical reference point for stakeholders involved in drug development, patent handling, and market positioning.
More… ↓
⤷ Start Trial
|
